More on FBIO
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.13 |
|
|||
| Open | $3.05 | ||||
| 52 Wk High | $4.66 | ||||
| 52 Wk Low | $2.01 | ||||
| Day High | $3.47 | ||||
| Day Low | $3.02 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 706,837 | ||||
- Fortress Biotech unit to sell rare disease voucher for $205 million
- UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
- Form 8-K Fortress Biotech, Inc. For: Feb 22
- Fortress Biotech unit Cyprium agrees to sell rare disease voucher for $205M
- Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
- Avenue Therapeutics licenses ATX-04 from Duke for Pompe disease treatment
- Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
- Form 8-K Fortress Biotech, Inc. For: Jan 13
- FDA approves ZYCUBO as first Menkes disease treatment
- Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
Entities mentioned with FBIO
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- S3 | View Related Stories »
- H.C. Wainwright | View Related Stories »
- B. Riley | View Related Stories »
- PDUFA | View Related Stories »
- Dividend | View Related Stories »
- Show More...
